Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine and Tenofovir for HERV-K Positive Lymphoma
NCT01528865Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lamivudine, tenofovir disoproxil fumarate in non-Hodgkin lymphoma (NHL), sponsored by University of Michigan Rogel Cancer Center. Planned start Dec 2015; status: withdrawn.
02
Drugs
lamivudinetenofovir disoproxil fumarate
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01528865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01528865.